Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huoling Shengji granules vs riluzole in ALS (TCM spleen qi deficiency, kidney yang deficiency)
CTR20202518Phase 2Completed
- Sponsor
- Shanghai University of Traditional Chinese Medicine
- Start
- Dec 2020
- Countries
- 1
01
Overview
A Phase 2 trial of Huoling Shengji Granules in amyotrophic lateral sclerosis (ALS), sponsored by Shanghai University of Traditional Chinese Medicine. Started Dec 2020; status: completed.
02
Drugs
Huoling Shengji Granules
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on CTR20202518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202518.